CorMedix (CRMD) Stock Price, News & Analysis

Company Overview

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

Key Stats

• Today's Range: $12.11 to $12.53
• 50-Day Range: $5.86 to $12.82
• 52-Week Range: $3.61 to $13.85
• Volume: 361,475 shs
• Average Volume: 1.16 million shs
• Market Capitalization: $819.39 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $15.00
• Consensus Rating: Buy

CorMedix Stock Analysis - MarketRank™

CorMedix scored higher than 40% of companies evaluated by MarketBeat, and ranked 644th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

CorMedix has received a consensus rating of Buy. The company's average rating score is 3.14, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

CorMedix has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for CorMedix are expected to grow in the coming year, from ($0.32) to $0.94 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of CorMedix is -15.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of CorMedix is -15.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

CorMedix has a P/B Ratio of 9.71. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

14.69% of the float of CorMedix has been sold short.

Short Interest Ratio / Days to Cover

CorMedix has a short interest ratio ("days to cover") of 4.6.

Change versus previous month

Short interest in CorMedix has recently increased by 5.10%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CorMedix does not currently pay a dividend.

Dividend Growth

CorMedix does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

14.69% of the float of CorMedix has been sold short.

Short Interest Ratio / Days to Cover

CorMedix has a short interest ratio ("days to cover") of 4.6.

Change versus previous month

Short interest in CorMedix has recently increased by 5.10%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 4.0 / 5
• News Sentiment: 1.23

News Sentiment

CorMedix has a news sentiment score of 1.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for CorMedix this week, compared to 4 articles on an average week.

Search Interest

7 people have searched for CRMD on MarketBeat in the last 30 days. This is an increase of 40% compared to the previous 30 days.

MarketBeat Follows

8 people have added CorMedix to their MarketBeat watchlist in the last 30 days. This is an increase of 700% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, CorMedix insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 5.20% of the stock of CorMedix is held by insiders.

Percentage Held by Institutions

Only 34.18% of the stock of CorMedix is held by institutions.

CRMD Stock Analysis - Frequently Asked Questions

How have CRMD shares performed this year?

CorMedix's stock was trading at $8.10 at the beginning of the year. Since then, CRMD shares have increased by 53.5% and is now trading at $12.43.
View the best growth stocks for 2025 here.

How were CorMedix's earnings last quarter?

CorMedix Inc. (NASDAQ:CRMD) announced its earnings results on Tuesday, May, 6th. The company reported $0.30 earnings per share for the quarter, topping the consensus estimate of $0.25 by $0.05. The company had revenue of $39.08 million for the quarter, compared to the consensus estimate of $38.90 million.
Read the conference call transcript.

When did CorMedix's stock split?

CorMedix shares reverse split before market open on Tuesday, March 26th 2019. The 1-5 reverse split was announced on Thursday, March 21st 2019. The number of shares owned by shareholders was adjusted after the closing bell on Monday, March 25th 2019. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

Who are CorMedix's major shareholders?

Top institutional investors of CorMedix include Vanguard Group Inc. (5.38%), Elliott Investment Management L.P. (3.60%), Palisades Investment Partners LLC (0.55%) and Invesco Ltd. (0.43%). Insiders that own company stock include Joseph Todisco, Erin Mistry and Elizabeth Hurlburt.
View institutional ownership trends.

How do I buy shares of CorMedix?

Shares of CRMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of CorMedix own?

Based on aggregate information from My MarketBeat watchlists, some other companies that CorMedix investors own include Voyager Therapeutics (VYGR), Waste Connections (WCN), American Water Works (AWK), DiamondRock Hospitality (DRH), AUO (AUOTY), Marinus Pharmaceuticals (MRNS) and The RMR Group (RMR).

Company Calendar

• Last Earnings: 5/06/2025
• Today: 5/29/2025
• Next Earnings (Estimated): 8/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CRMD
• CIK: 1410098
• Web: www.cormedix.com
• Phone: (908) 517-9500
• Fax: 908-429-4307
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $15.00
• High Stock Price Target: $18.00
• Low Stock Price Target: $12.00
• Potential Upside/Downside: +20.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.14
• Research Coverage: 7 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $0.22
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$46.34 million
• Net Margins: N/A
• Pretax Margin: -387.73%
• Return on Equity: -79.21%
• Return on Assets: -64.68%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.96
• Quick Ratio: 3.60

Sales & Book Value

• Annual Sales: $82.55 million
• Price / Sales: 10.21
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.28 per share
• Price / Book: 9.71

Miscellaneous

• Outstanding Shares: 67,825,000
• Free Float: 57,522,000
• Market Cap: $843.06 million
• Optionable: Optionable
• Beta: 1.54